<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BCDAA08B-E17D-4C05-9863-633154098726"><gtr:id>BCDAA08B-E17D-4C05-9863-633154098726</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Thaventhiran</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL006197%2F1"><gtr:id>44C4A172-79E9-4A07-84D4-1897F7828D43</gtr:id><gtr:title>Defining the role of STAT1 acetylation in adaptive immunity.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/L006197/1</gtr:grantReference><gtr:abstractText>The immune system works by recognising pathogens as foreign and initiating a response that destroys the invader. In auto-immune disease, however, it is the host that is mistakenly thought to be foreign and so destroyed by the subsequent immune response. Both immune and auto-immune responses are dependent on an incredible expansion (&amp;gt;10,000fold) in the number of cells capable of recognising what is foreign. This expansion in number occurs by cellular proliferation. What is surprising is that such proliferation still occurs in environments that we would expect to be anti-proliferative because of their high levels of the anti-pathogen protein, interferon (IFN). This project tests the hypothesis that this proliferation can occur because the cells of the immune system modify the IFN signalling molecule STAT1. Experiments will test whether blocking this step prevents both protective immune responses and protects against the autoimmune disease, SLE. These experiments will also generate the materials necessary to test whether HIV owes part of its infectious success to its exploitation of this mechanism. The overall aim of the project is to reduce to a single biochemical event the complex physiological reactions that drive both immune protection and autoimmunity, in order to open new avenues for treatments.</gtr:abstractText><gtr:technicalSummary>Preliminary data demonstrates that antigen, the initiator of proliferation in adaptive immunity, dramatically alters the anti-viral and anti-proliferative transcriptional effects of IFN. Further experiments suggest that this occurs by the acetylation of STAT1. This proposal tests this hypothesis and defines antigen-induced STAT1 acetylation's role in adaptive immune responses.

A conditional BAC transgenic murine model, in which lymphocytes only express acetylation-resistant STAT1, with normal STAT1 elsewhere, will be developed to interrogate acetylated-STAT1's function. The model will define the significance of STAT1 acetylation in protective immune responses by challenging the mice with antigen, delivered by vaccination and virus, and assaying their adaptive immune responses. By challenge of the mice with pristane to induce murine lupus, I will investigate the role of lymphocyte acetylation in auto-immunity. To investigate how acetylation alters STAT1 responses, I will use the cutting-edge technical innovation of orthogonal unnatural amino-acid incorporation to generate site-specifically
acetylated STAT1. Using a combination of surface plasmon resonance, confocal microscopy, immunoprecipitation and western blotting, acetylated STAT1 will be assessed for binding to nuclear importins, cellular localisation and phosphorylation. Translational experiments will then test the hypothesis that antigen, by acetylating STAT1 and blocking anti-viral IFN signalling, leaves CD4+ T cells susceptible to the T cell tropic
virus, HIV. Human CD4+ T lymphocytes expressing acetylated STAT1 and acetylation-resistant STAT1 will be assayed for HIV resistance using pseudotyped virus.

With the murine model, modified human cell lines and staff training gained from this, I will then be poised to further apply these findings to the specific murine and cell biological models of the extensive range of human illness affected by adaptive immunity and STAT1.</gtr:technicalSummary><gtr:potentialImpactText>The principal impact of this research will be for scientific and medical researchers studying adaptive immunity (as detailed under 'academic beneficiaries') and for the clinical immunology community within the U.K. The research will also have potential impact on the pharmaceutical industry, patient groups, and the wider public, via the channels detailed in my 'pathways to impact' statement.

One of the major routes for this impact will be the training of an academic clinical immunologist. 
NHS service provision in this field is currently from established academic centres that care for the complex needs of patients with severe immunedysfunction and is world-leading. This excellence has been driven both by the pioneering work of clinical academics, using research to lay down clinical standards, and by the recent growth in the number of clinical specialists. There has not, however, been a similar growth in the number of clinical academics. While over 70% of paediatric immunologists are clinical academics, in the adult service, less than 30% of immunologists hold primarily academic positions. Divorcing adult immunology service provision from clinical academia has the negative impact of reducing the translation of scientific advances into patient care. The reduction of interactions between clinical trainees and academia is also limiting the potential for new research leaders to emerge. A major aim of this fellowship proposal is to offset these negative trends by providing a model of training. 

A successful academic clinical immunologist has the potential to make an impact both on industry and on the interested members of the public. With regard to the former, the research aims to define a biochemical reaction necessary for adaptive immunity and this potentially opens up new avenues of therapeutic endeavour and new targets for licensed medication. This will be of direct interest to the U.K. pharmaceutical industry and the tools developed in the proposed research may also be used in industrial endeavours extending beyond the current proposal. With regard to the latter, successful research in this area would be very positive for the patient groups representing primary immunodeficiency, who have noted the decrease in academic links in adult NHS service provision
and who would welcome any increase in this capacity.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1134013</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Cambridge Biomedical Research Centre</gtr:department><gtr:description>Pilot project grant</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>D5BBDF04-49DF-41B5-AD3E-B36E582207CA</gtr:id><gtr:outcomeId>545a83fa5ec011.58393762</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Cambridge Biomedical Research Centre</gtr:department><gtr:description>Cambridge BRC RCF award</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>111ED11D-8039-476A-941D-F921EC713429</gtr:id><gtr:outcomeId>545a83b23132e1.05930153</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D3F7DE07-435B-4441-AC3E-646AFFE43FDE</gtr:id><gtr:title>Disseminated Mycobacterium malmoense and Salmonella Infections Associated with a Novel Variant in NFKBIA.</gtr:title><gtr:parentPublicationTitle>Journal of clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c409102c42112481aadb994a365903c"><gtr:id>3c409102c42112481aadb994a365903c</gtr:id><gtr:otherNames>Staples E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0271-9142</gtr:issn><gtr:outcomeId>58ff1fc0cc4412.29284104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB4CA6AC-73D2-4407-9A27-682994573130</gtr:id><gtr:title>The evolution of cellular deficiency in GATA2 mutation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c28551404bc2b202da3d3e5fda1bb112"><gtr:id>c28551404bc2b202da3d3e5fda1bb112</gtr:id><gtr:otherNames>Dickinson RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>545a82e9f3bea2.21783553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3C155BB-13DA-4A2B-B78E-E4DA4E4CD16B</gtr:id><gtr:title>Phenotypic Characterization ofMutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01c5e945aa307d1ad0be78b05f4d2293"><gtr:id>01c5e945aa307d1ad0be78b05f4d2293</gtr:id><gtr:otherNames>Hadinnapola C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>5a95f282c8e661.36982352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13B270F9-7798-4C10-9541-84278DF58693</gtr:id><gtr:title>Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61711e17c223459294a27a3946aed64a"><gtr:id>61711e17c223459294a27a3946aed64a</gtr:id><gtr:otherNames>Carss KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>58ff20053d6b93.66907913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>010DBFE6-7A2F-45D5-86B0-D45AD33EC691</gtr:id><gtr:title>Prevalence and clinical challenges among adult primary immunodeficiency patients with RAG deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f594f6d5f607deadc556c8488fb65aa1"><gtr:id>f594f6d5f607deadc556c8488fb65aa1</gtr:id><gtr:otherNames>Lawless D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5a95f16f36d4c2.19547944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE03B103-9DCC-4AEE-BE73-CFA9DA03A9E3</gtr:id><gtr:title>A Type III Complement Factor D Deficiency: Structural insights for inhibition of the alternative pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c4ff4ceefdc4de56a0452622f6196ae"><gtr:id>3c4ff4ceefdc4de56a0452622f6196ae</gtr:id><gtr:otherNames>Sng CCT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5aa67b54c3a343.82287261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AADBCD3-EFEE-4726-B5F4-2A3C0BE33D1F</gtr:id><gtr:title>Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a11d973ca4f3b4064143824a7f4f8344"><gtr:id>a11d973ca4f3b4064143824a7f4f8344</gtr:id><gtr:otherNames>Farmery JHR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a95f2829a5c94.37161298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FB131F-ABA3-4537-A596-3D49F69EA6A9</gtr:id><gtr:title>Loss of function NFKB1 variants are the most common monogenic cause of CVID in Europeans.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab29d7ab13e9cfa0e9a4a133d6660b95"><gtr:id>ab29d7ab13e9cfa0e9a4a133d6660b95</gtr:id><gtr:otherNames>Tuijnenburg P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>5a95f224a40541.18309575</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L006197/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>